JBIO
Jade Biosciences, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Jade Biosciences, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
No other changes.
No other changes.
No thesis.
Annual filing, covered
10-K parsed · Mar 6 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 6 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
−1.05%
vs ±18.9% implied · ×0.06
shaded = implied · ▲▼ = realized
Jade Biosciences, Inc.
14.55
pre 14.55 +4.41%
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Jade Biosciences, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Jade Biosciences, Inc.'s 6 closest co-movers, none share that code.
| Manager | Value | % base | |
|---|---|---|---|
| FMR | $202.8M | 12.50% | +28.81% |
| Jupiter Topco | $139.4M | 8.59% | — |
| Fairmount Funds | $101.2M | 6.24% | 0.00% |
| RA Capital Management | $81.6M | 5.03% | 0.00% |
| VR Adviser | $71.6M | 4.41% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| FMR | $202.8M | 12.50% | +28.81% |
| Jupiter Topco | $139.4M | 8.59% | — |
| Fairmount Funds | $101.2M | 6.24% | 0.00% |
| RA Capital Management | $81.6M | 5.03% | 0.00% |
| VR Adviser | $71.6M | 4.41% | 0.00% |
—
—
Bull3
Bear2
Tall tick = annual report · Source: EDGAR
Largest filed tie
—
Expected move
No implied move.